Smallwood Natasha, Gaffney Nicole, Gorelik Alexandra, Irving Louis, Le Brian, Philip Jennifer
Department of Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Respiratory Medicine, Frankston Hospital, Melbourne, Victoria, Australia.
Intern Med J. 2017 Sep;47(9):1050-1056. doi: 10.1111/imj.13521.
Refractory breathlessness is a common, distressing symptom in patients with advanced chronic obstructive pulmonary disease (COPD). The judicious, off-licence prescription of opioids, together with other management strategies, can improve breathlessness, however, internationally there is profound reluctance to prescribe opioids for breathlessness in COPD.
To understand Australian junior doctors' knowledge and attitudes regarding the management of refractory breathlessness and the role of opioids in COPD.
All junior doctors undertaking basic training in internal medicine in Victoria were invited to complete an online survey. Knowledge, willingness, and experience prescribing opioids to COPD patients with refractory breathlessness, were examined.
Of the 243 responses received, most trainees (193, 86.5%) believed opioids have a role in treating refractory breathlessness in stable COPD outpatients, with 143 (64.1%) recommending morphine as first-line treatment for refractory breathlessness. One quarter (55, 24.7%) reported having themselves initiated an opioid and 102 (45.7%) had prescribed an opioid under senior supervision for management of breathlessness in COPD. Concern regarding adverse opioid effects was low, with 58 (26.0%) having no concerns prescribing an opioid to COPD patients.
This is the first study of doctors to demonstrate high awareness, confidence, willingness and experience in prescribing opioids for the off-licence indication of refractory breathlessness in COPD. These findings differ significantly from attitudes reported overseas and are unexpected given the doctors surveyed were recently qualified. The low awareness of possible adverse events and limited insight regarding knowledge gaps is concerning and highlights the significant need for greater education in palliative care.
难治性呼吸困难是晚期慢性阻塞性肺疾病(COPD)患者常见且令人痛苦的症状。合理地超适应证使用阿片类药物,结合其他管理策略,可以改善呼吸困难,然而,在国际上,对于在COPD中因呼吸困难而开具阿片类药物存在很大的抵触情绪。
了解澳大利亚初级医生关于难治性呼吸困难管理的知识和态度,以及阿片类药物在COPD中的作用。
邀请所有在维多利亚州接受内科基础培训的初级医生完成一项在线调查。调查内容包括给患有难治性呼吸困难的COPD患者开具阿片类药物的知识、意愿和经验。
在收到的243份回复中,大多数受训者(193人,86.5%)认为阿片类药物在治疗稳定期COPD门诊患者的难治性呼吸困难中发挥作用,143人(64.1%)推荐吗啡作为难治性呼吸困难的一线治疗药物。四分之一(55人,24.7%)报告自己曾开具过阿片类药物,102人(45.7%)曾在上级监督下为COPD患者的呼吸困难管理开具过阿片类药物。对阿片类药物不良反应的担忧较低,58人(26.0%)在给COPD患者开具阿片类药物时没有顾虑。
这是第一项针对医生的研究,表明医生在为COPD难治性呼吸困难的超适应证开具阿片类药物方面具有较高的认知度、信心、意愿和经验。这些发现与海外报告的态度有显著差异,鉴于接受调查的医生是近期获得资格的,这一结果出人意料。对可能的不良事件认识不足以及对知识差距的了解有限令人担忧,凸显了在姑息治疗方面加强教育的迫切需求。